Avyansh Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 2 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.15 Cr
as on 20-12-2024
About Avyansh Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.15 Cr.
Yatinkumar Patel, Chandrikaben Patel, Mitenkumar Shah, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290GJ2022PTC136292
- Company No.
136292
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Avyansh Formulations?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yatinkumar Patel  | Director | 19-Oct-2022 | Current |
| Chandrikaben Patel | Director | 19-Oct-2022 | Current |
| Mitenkumar Shah | Director | 19-Oct-2022 | Current |
| Nirajkumar Shah | Director | 19-Oct-2022 | Current |
| Jay Butani | Director | 19-Oct-2022 | Current |
Financial Performance of Avyansh Formulations.
Avyansh Formulations Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Avyansh Formulations?
Unlock access to Avyansh Formulations's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Acnova Pharmaceuticals Private LimitedActive 2 years 3 months
Yatinkumar Patel and Chandrikaben Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Jan 2023 | ₹4.00 Cr | Open |
Others Creation Date: 24 Jan 2023 | ₹1.50 M | Open |
Others Creation Date: 04 Jan 2023 | ₹4.00 Cr | Open |
How Many Employees Work at Avyansh Formulations?
Unlock and access historical data on people associated with Avyansh Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avyansh Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avyansh Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
